Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BPI-15086 in EGFR T790M+ NSCLC
NCT02914990Phase 1Completed
- Sponsor
- Betta Pharmaceuticals
- Start
- Dec 2016
- Primary completion
- Mar 2019
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BPI-15086 in non-small cell lung cancer (NSCLC), sponsored by Betta Pharmaceuticals. Primary endpoint: Adverse events at 18 months. Started Dec 2016; status: completed.
02
Drugs
BPI-15086
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02914990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02914990.